Reference - Detail
| RRC ID | 68572 |
|---|---|
| Author | Nakamura T, Fukiage M, Higuchi M, Nakaya A, Yano I, Miyazaki J, Nishiyama H, Akaza H, Ito T, Hosokawa H, Nakayama T, Harashima H. |
| Title | Nanoparticulation of BCG-CWS for application to bladder cancer therapy. |
| Journal | J Control Release |
| Abstract |
The Mycobacterium bovis Bacille Calmette-Guerin cell wall skeleton (BCG-CWS) could be used to replace live BCG as a bladder cancer drug. However, because BCG-CWS is poorly soluble, has a strong-negative charge, very high molecular weight and heterogeneity in size of tens of μm, it cannot be used in such an application. We report herein on the development of a novel packaging method that permits BCG-CWS to be encapsulated into 166nm-sized lipid particles. The BCG-CWS encapsulated nano particle (CWS-NP) has a high uniformity and can be easily dispersed. Thus, it has the potential for use as a packaging method that would advance the scope of applications of BCG-CWS as a bladder cancer drug. In a functional evaluation, CWS-NP was efficiently taken up by mouse bladder tumor (MBT-2) cells in vitro and inhibited tumor growth in mice bearing MBT-2 tumors. Moreover, intravesically administered CWS-NP showed significant antitumor effects in a rat model with naturally developed bladder cancer. An enhancement in Th1 differentiation by CWS-NP was also confirmed in human T cells. In conclusion, CWS-NP represents a promising delivery system for BCG-CWS for clinical development as a potent bladder cancer drug. |
| Volume | 176 |
| Pages | 44-53 |
| Published | 2014-2-28 |
| DOI | 10.1016/j.jconrel.2013.12.027 |
| PII | S0168-3659(13)00969-3 |
| PMID | 24389133 |
| MeSH | Adult Animals Antineoplastic Agents / administration & dosage* Butylhydroxybutylnitrosamine Cell Differentiation / drug effects Cell Line, Tumor Cell Wall Skeleton / administration & dosage* Cells, Cultured Female Humans Male Mice Mice, Inbred C3H Mycobacterium bovis* Nanoparticles / administration & dosage* Rats Rats, Inbred F344 T-Lymphocytes / cytology T-Lymphocytes / drug effects Urinary Bladder Neoplasms / chemically induced Urinary Bladder Neoplasms / drug therapy* Young Adult |
| IF | 7.727 |
| Altmetric score |
オルトメトリクス指標項目
|
| The most frequently cited source | Patent(IFI CLAIMS) |
| Total number of mentions | 14 |
| Altmetric score changes over past 6months | 0.0 |
| Resource | |
| Human and Animal Cells | MBT-2(RCB0544) |